Olympus推出新型C反应蛋白乳胶检测方法

 
一种新型C反应蛋白乳胶检测方法，已经被研制作为心脏疾病的独立危险指标。该检测方法已经获得美国食品药品管理局的许可。

这种新型检测方法是由Olympus诊断系统集团研制开发的，其母公司是Olympus集团。Olympus指出这种高度敏感的检测方法，与传统临床实验室评估手段相结合，可以作为稳定型冠心病或者急性冠脉综合征患者复发事件预后的独立指标。

C反应蛋白是最敏感的急性时相反应物的一种。CRP的检测在检测和评估感染、组织损伤和炎症性疾病以及其他相关疾病中，扮演着重要角色。这种CRP乳胶检测提供了3种检测方法，覆盖了人血清中含量范围广泛的CRP：正常(5～170 mg/l)、敏感(0.5～20 mg/l)和高度敏感(新生儿：0.05～2.00 mg/l)。这种检测可以在所有Olympus 化学免疫分析仪上操作。

Olympus提供了各种化学免疫分析仪、实验室自动化系统、广泛的患者安全系统、血库分析仪和试剂。

New Latex CRP Assay
 
A new c-reactive protein (CRP) latex assay has been developed as an independent cardiac risk marker. The assay has been cleared by the U.S. Food and Drug Administration (FDA).

The new assay was developed by Olympus Diagnostic Systems Group (Melville, NY, USA), whose parent company is Olympus Corp. (Tokyo, Japan). Olympus notes that highly sensitive application measurements when used in conjunction with traditional clinical laboratory evaluations maybe useful as an independent marker of prognosis for recurrent events in patients with either stable coronary disease or acute coronary syndromes.

C-reactive protein is one of the most sensitive acute-phase reactants. Measurement of CRP can play a role in the detection and evaluation of infection, tissue injury, and inflammatory disorders and related diseases. The CRP latex assay offers three applications covering a variety of measuring ranges to quantify CRP in human serum: normal (5 to 170 mg/l), sensitive (0.5 to -20 mg/l), and highly sensitive (neonatal, 0.05 to 2.00 mg/l). The assay can be run on the full line of Olympus chemistry-immuno analyzers.

Olympus offers a broad line of random access chemistry-immuno analyzers along with lab automation systems, comprehensive patient safety systems, blood bank analyzers, and reagents.